Department of Cardiothoracic Surgery, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.
Cardiovascular Precision Laboratory, The University of Sydney, Sydney, New South Wales, 2006, Australia.
ESC Heart Fail. 2022 Feb;9(1):21-30. doi: 10.1002/ehf2.13768. Epub 2021 Dec 21.
Biobanking in health care has evolved over the last few decades from simple biological sample repositories to complex and dynamic units with multi-organizational infrastructure networks and has become an essential tool for modern medical research. Cardiovascular tissue biobanking provides a unique opportunity to utilize cardiac and vascular samples for translational research into heart failure and other related pathologies. Current techniques for diagnosis, classification, and treatment monitoring of cardiac disease relies primarily on interpretation of clinical signs, imaging, and blood biomarkers. Further research at the disease source (i.e. myocardium and blood vessels) has been limited by a relative lack of access to quality human cardiac tissue and the inherent shortcomings of most animal models of heart disease. In this review, we describe a model for cardiovascular tissue biobanking and databasing, and its potential to facilitate basic and translational research. We share techniques to procure endocardial samples from patients with hypertrophic cardiomyopathy, heart failure with reduced ejection fraction, and heart failure with preserved ejection fraction, in addition to aortic disease samples. We discuss some of the issues with respect to data collection, privacy, biobank consent, and the governance of tissue biobanking. The development of tissue biobanks as described here has significant scope to improve and facilitate translational research in multi-omic fields such as genomics, transcriptomics, proteomics, and metabolomics. This research heralds an era of precision medicine, in which patients with cardiovascular pathology can be provided with optimized and personalized medical care for the treatment of their individual phenotype.
生物库在医疗保健中的发展在过去几十年中经历了从简单的生物样本库到具有多组织基础设施网络的复杂和动态单元的转变,并且已经成为现代医学研究的重要工具。心血管组织生物库为利用心脏和血管样本进行心力衰竭和其他相关病理的转化研究提供了独特的机会。目前,心脏病的诊断、分类和治疗监测主要依赖于对临床症状、影像学和血液生物标志物的解释。由于获取高质量的人类心脏组织的机会相对较少,以及大多数心脏病动物模型的固有缺陷,对疾病源(即心肌和血管)的进一步研究受到限制。在这篇综述中,我们描述了心血管组织生物库和数据库的模型,以及它促进基础和转化研究的潜力。我们分享了从肥厚型心肌病、射血分数降低的心力衰竭和射血分数保留的心力衰竭患者以及主动脉疾病样本中获取心内膜样本的技术。我们讨论了一些与数据收集、隐私、生物库同意和组织生物库管理有关的问题。如基因组学、转录组学、蛋白质组学和代谢组学等多组学领域的转化研究具有显著的改善和促进作用。这项研究预示着精准医学的时代的到来,患有心血管病理的患者可以获得针对其个体表型的优化和个性化医疗护理。